SERBP1 was positive in 28.6% of those with grade I gliomas, 55.6% of those with grade II gliomas, 83.3% of those with grade III gliomas, and 89.0% of those with grade IV gliomas (P < 0.001). The gene discussed is SERBP1; the disease is central nervous system cancer.